Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Benjamin Besse, MD, PhD"'
Autor:
Marco Tagliamento, MD, Jordi Remon, MD, PhD, Matteo Giaj Levra, MD, Andrea De Maria, MD, Paolo Bironzo, MD, PhD, Benjamin Besse, MD, PhD, Silvia Novello, MD, PhD, Laura Mezquita, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100446- (2023)
Introduction: Patients with cancer and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are underrepresented in several clinical trials testing immune checkpoint inhibitors (ICIs). Consequently, safety and efficacy of ICI therapy in this
Externí odkaz:
https://doaj.org/article/8bb0b046a4dc4b03923440db7ca7bf49
Autor:
Jordi Remon, MD, Benjamin Besse, MD, PhD, Alexandra Leary, MD, PhD, Ivan Bièche, MD, Bastien Job, MD, Ludovic Lacroix, PhD, Aurélie Auguste, PhD, Marjorie Mauduit, PhD, Clarisse Audigier-Valette, MD, Judith Raimbourg, MD, Anne Madroszyk, MD, Stefan Michels, MD, Mohammed Amine Bayar, MD, Marta Jimenez, PhD, Jean-Charles Soria, MD, PhD, Etienne Rouleau, PhD, PharmD, MPH, Fabrice Barlesi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100068- (2020)
Introduction: Molecular profiling is considered a standard of care in advanced NSCLC. A comprehensive next-generation sequencing panel can discover somatic or germline BRCA1/2 mutations that are new druggable molecular alterations. However, the pheno
Externí odkaz:
https://doaj.org/article/cb706811cafb4c91896d59398b20d6b7
Autor:
Diego Enrico, MD, Ludovic Lacroix, PharmD, PhD, Jeanne Chen, MD, Etienne Rouleau, PharmD, PhD, Jean-Yves Scoazec, MD, PhD, Yohann Loriot, MD, PhD, Lambros Tselikas, MD, Cécile Jovelet, PharmD, PhD, David Planchard, MD, PhD, Anas Gazzah, MD, Laura Mezquita, MD, PhD, Maud Ngo-Camus, MSc, Stefan Michiels, PhD, Christophe Massard, MD, PhD, Gonzalo Recondo, MD, PhD, Francesco Facchinetti, MD, Jordi Remon, MD, Jean-Charles Soria, MD, PhD, Fabrice André, MD, PhD, Gilles Vassal, MD, PhD, Luc Friboulet, PhD, Benjamin Besse, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100023- (2020)
Introduction: Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple mechanisms. Recent reports have identified oncogenic kinase fusions
Externí odkaz:
https://doaj.org/article/1bd1d67570ef49619261081550260f89